
Sanofi Korea wins approval to expand Dupixent indication for certain COPD patients
Sanofi Korea said on Friday that its atopic dermatitis drug Dupixent (dupilumab) has expanded its indication to include add-on maintenance therapy for adults with chronic obstructive pulmonary disease (COPD) who have an elevated blood eosinophil count and …